| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
4-Methoxycinnamic acid ethyl ester (25-200 μg/mL, 0-48 h) inhibited the growth of HUVECs with an IC50 of 160 μg/mL and inhibited the migration ability of HUVECs by VEGF [2]. 4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 6-24 h) dose-dependently impaired the ability of HUVECs to form tubular structures on Matrigel [2]. 4-Methoxycinnamic acid ethyl ester (50-200 μg/mL, 5 d) significantly inhibited the sprouting and growth of microvessels in the aortic ring of rats [2]. 4-Methoxycinnamic acid ethyl ester (0.03–0.97 mM, 7 d) inhibited Mycobacterium tuberculosis H37Ra, H37Rv, drug-sensitive and multidrug-resistant (MDR) clinical isolates (MIC: 0.242–0.485 mM), and was ineffective against common bacteria such as Mycobacterium smegmatis, Escherichia coli and Staphylococcus aureus [3]. 4-Methoxycinnamic acid ethyl ester (50 μM, 12 h) significantly reduced the phosphorylation levels of p-p65 (Ser536) and p-Akt (Ser473) in melanoma cells [4]. 4-Methoxycinnamic acid ethyl ester (50 μM, 24 h) significantly inhibited the migration and invasion of melanoma cells [4]. 4-Methoxycinnamic acid ethyl ester (1-50 μM, 12-24 h) reversed the resistance of melanoma cells to Paclitaxel[4]. 4-Methoxycinnamic acid ethyl ester (125-500 μM, 24 h) showed broad-spectrum antiviral activity against all four dengue serotypes (DENV-1, DENV-2, DENV-3, DENV-4), with EC50 values of 22.58 and 6.17 μM against DENV-2 in HepG2 and A549 cells, respectively[5]. 4-Methoxycinnamic acid ethyl ester (100 μM, 1-24 h) inhibited de novo fatty acid synthesis (rather than glycolysis) in Ehrlich ascites carcinoma cells (EATCs), thereby depleting ATP[6]. 4-Methoxycinnamic acid ethyl ester (48 h) showed moderate cytotoxicity against MCF-7, HT-29, HCT-116 (IC50 = 42.1 μg/mL), U-937, PC-3 (IC50 = 39 μg/mL), and K-562 cells [7]. 4-Methoxycinnamic acid ethyl ester (50–200 μg/mL, 12–48 h) inhibited the migration of HCT-116 cells and induced apoptosis via the mitochondrial pathway [7]. 4-Methoxycinnamic acid ethyl ester (200 μg/mL, 8 h) significantly activated all tested caspases, including caspase-9, caspase-8, and caspase-3/7, in HCT-116 cells [7].
|
|---|---|
| ln Vivo |
Ethyl 4-methoxycinnamate (100-800 mg/kg, single gavage) was administered in the field via monitoring to reduce paw edema[1]. Ethyl 4-methoxycinnamate (200-800 mg/kg, single gavage for 7 consecutive days) was administered in the field via reporting to reduce chronic granuloma formation[2]. (200-800 mg/kg, single gavage) was administered in a dose-dependent manner to prolong the latency period of tail hanging and showed significant analgesic effects[2].
|
| Cell Assay |
Cell Migration Assay [2]
Cell Types: HUVECs Tested Concentrations: 50, 100, 200 μg/mL Incubation Duration: 0, 6 and 12 h Experimental Results: Effectively prevented the migration of endothelial cells to the damaged area. Western Blot Analysis[4] Cell Types: B16F10 G5-Luc and SK-Mel 28 Tested Concentrations: 50 μM Incubation Duration: 12 h (B16F10 G5-Luc) and 24 h (SK-Mel 28) Experimental Results: Significantly reduced the phosphorylation levels of p-p65 (Ser536) and p-Akt (Ser473). Upregulated the expression of γ-H2AX with Paclitaxel. Cell Migration Assay [4] Cell Types: B16F10 G5-Luc Tested Concentrations: 50 μM Incubation Duration: 12 h Experimental Results: Significantly inhibited the migration. Cell Invasion Assay[4] Cell Types: B16F10 G5-Luc Tested Concentrations: 50 μM Incubation Duration: 12 h Experimental Results: Significantly reduced the number of cells passing through Matrigel. Western Blot Analysis[4] Cell Types: 143B cells Tested Concentrations: 2.5 μM Incubation Duration: 1, 2, 4, 8, 16 and 24 h Experimental Results: Activated caspases and increased PARP-1 cleavage. Promoted the phosphorylation of p53, and upregulated PUMA and Bax. Increased the level of γH2AX. RT-PCR[6] Cell Types: EATCs Tested Concentrations: 100 μM Incubation Duration: 1, 6 and 12 h Experimental Results: Significantly downregulated the mRNA expression of key enzymes in fatty acid synthesis, including Acly, Acc1, and Fasn. Was no significant effect on the mRNA expression of key fatty acid oxidation enzymes Cpt1a and Cpt1b. Significantly downregulated the expression levels of SREBP1 mRNA. Western Blot Analysis[6] Cell Types: EATCs Tested Concentrations: 100 μM Incubation Duration: 1, 6 and 12 h Experimental Results: Significantly reduced the phosphorylation level of c-Myc protein Ser62 site. Downregulated the expression of key enzymes in fatty acid synthesis (Acly, Acc1, Fasn). Apoptosis Analysis[7] Cell Types: HCT-116 Tested Concentrations: 50, 100, 200 μg/mL Incubation Duration: 48 h Experimental Results: Dose-dependently induced chromatin condensation in HCT-116 cells. Dose-dependent lost mitochondrial membrane potential. |
| Animal Protocol |
Animal/Disease Models: Carrageenan-induced paw edema model established in male Sprague Dawely (SD) rats (150-200 g)[1]
Doses: 100, 200, 400 and 800 mg/kg Route of Administration: Oral gavage (i.g.), single dose Experimental Results: Inhibited paw edema in a dose-dependent manner, with the minimum effective dose (MIC) being 100 mg/kg. No toxic reactions were observed at 2000 mg/kg. Animal/Disease Models: Cotton pellet granuloma assay established in male Sprague Dawely (SD) rats (200-250 g)[2] Doses: 200, 400, 800 mg/kg Route of Administration: Oral gavage (i.g.), once daily for 7 days Experimental Results: Reached inhibition rate by 51.65% at 800 mg/kg. Inhibited the production of key pro-inflammatory cytokines IL-1β and TNF-α. Animal/Disease Models: Tail flick assay established in male Sprague Dawely (SD) rats (200-250 g)[2] Doses: 200, 400, 800 mg/kg Route of Administration: Oral gavage (i.g.), single dose Experimental Results: Prolonged the tail-flick latency of rats in a dose-dependent manner |
| References |
|
| Molecular Formula |
C12H14O3
|
|---|---|
| Molecular Weight |
206.24
|
| Exact Mass |
206.094
|
| CAS # |
1929-30-2
|
| Related CAS # |
(E)-Ethyl p-methoxycinnamate; 24393-56-4
|
| PubChem CID |
5281783
|
| Appearance |
Typically exists as solids at room temperature
|
| Melting Point |
49 - 50 °C
|
| Hydrogen Bond Donor Count |
0
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
15
|
| Complexity |
215
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(=O)/C=C/C1=CC=C(C=C1)OC
|
| InChi Key |
DHNGCHLFKUPGPX-RMKNXTFCSA-N
|
| InChi Code |
InChI=1S/C12H14O3/c1-3-15-12(13)9-6-10-4-7-11(14-2)8-5-10/h4-9H,3H2,1-2H3/b9-6+
|
| Chemical Name |
ethyl (E)-3-(4-methoxyphenyl)prop-2-enoate
|
| Synonyms |
Ethyl p-methoxycinnamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8487 mL | 24.2436 mL | 48.4872 mL | |
| 5 mM | 0.9697 mL | 4.8487 mL | 9.6974 mL | |
| 10 mM | 0.4849 mL | 2.4244 mL | 4.8487 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
